Phase I trial of combined chemotherapy of bevacizumab, panitumumab and irinotecan as 3rd-line chemotherapy in chmotherapy-refractory metastatic colorectal cancer.
收藏NIAID Data Ecosystem2026-03-07 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2624760
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: Combined chemotherapy of bevacizumab, panitumumab, irinotecan.
Primary outcome(s): Proportion of dose limiting toxicity (DLT).
Study Design: Single arm Non-randomized
创建时间：
2012-11-15
